NCT04150471View on ClinicalTrials.gov

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

UnknownOBSERVATIONAL

Enrollment

79

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2023

Conditions

Chronic Myelocytic Leukemia

Interventions

OTHER

RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis

Conventional Q-RT-PCR every 3 months

Trial Locations (1)

137-701

RECRUITING

Seoul St. Mary's Hospital, Seoul

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER